A situação atual do mercado da saúde suplementar no Brasil e apontamentos para o futuro

Albuquerque, Ceres; Piovesan, Márcia Franke; Santos, Isabela Soares; Martins, Ana Cristina; Fonseca, Artur Lourenço da; Sasson, Daniel C; Simões, Kelly

doi:10.1590/s1413-81232008000500008

Cited by 36 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Under this perspective, the quest for a treatment, at least, as effective and less costly compared to others currently covered by companies becomes key to guaranteeing the financial sustainability of the system. This is required especially if we consider the current scenario of growing casuistic and decreasing profitability of supplementary healthcare insurance companies (Albuquerque et al, 2008), in addition to the increased population life expectancy (Azevedo, 2010). Certolizumab pegol in several studies has been shown as effective and safe as other anti-TNF agents available to treat CD (Shao et al, 2009;Singh et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Rosim¹,

Duva²,

Ferraz³

et al. 2017

JBES

View full text Add to dashboard Cite

Objectives: Budget impact and cost-effectiveness analysis are often required by payers when discussing drug reimbursement. We hereby present a cost-minimization (CMA) and budget impact analysis (BIA) regarding the incorporation of certolizumab pegol (CZP) for the treatment of patients with Crohn's disease, a debilitating condition that affects the digestive tract. Methods: Considering that the scientific literature demonstrates CZP as effective as the alternatives (infliximab and adalimumab), a CMA was conducted, including a Markov 10-year time horizon modeling. Focusing on the assumptions for both CMA and BIA, a total of 36 stakeholders from the private sector were surveyed regarding treatment and disease-related costs. For the BIA, drug acquisition costs, administration costs, no population growth and an immunobiologic drug (bDMARD) switching rate of 5% were also considered. We assumed that CZP would gradually gain market share until it reaches 20% of new or switching patients in the fourth year. In addition, probability sensitivity analyses were performed. Results: In the cost-minimization, the calculated costs for 10-year treatment were BRL149k (infliximab); BRL118k (adalimumab) and BRL83k (CZP). Probabilistic sensitivity analysis was conducted with 1,000 random simulations, with CZP being less costly than its comparators in all simulations. Additionally, the BIA result indicates that CZP is a cost-saving intervention, with a predicted five-year impact of BRL317k for every 100-patient cohort. Conclusions: Certolizumab pegol was shown to be not only effective but also a cost-saving drug when compared to other anti-TNF drugs available for the Brazilian private healthcare system. RESUMOObjetivos: Análises de impacto orçamentário e de custo-efetividade são, com frequência, exigidas por pagadores para a decisão sobre incorporação de drogas. Por esse motivo, apresentaremos uma análise de custo-minimização e de impacto orçamentário do certolizumabe pegol (CZP) para o tratamento de pacientes com doença de Crohn, doença crônica e debilitante que afeta o trato digestivo. Métodos: Trinta e seis pagadores privados foram entrevistados para que fosse possível

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Rosim¹,

Duva²,

Ferraz³

et al. 2017

JBES

View full text Add to dashboard Cite

show abstract

“…9.656/98 e a criação da ANS, ter se verificado uma melhoria na quantidade e qualidade de dados sobre o mercado de saúde suplementar, ele ainda é pouco conhecido e considerado no planejamento do sistema de saúde no país. Essa questão assume grande relevância, em face da abrangência do setor, assim como da sua forte relação com o setor público 10 .…”

Section: Discussionunclassified

Estrutura e qualidade assistencial dos prestadores de serviços hospitalares à saúde suplementar no Brasil

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Conforme Albuquerque et al (2008), as operadoras estão organizadas em modalidades, segundo seu estatuto jurídico: …”

Section: A Saúde Suplementar E No Brasilunclassified

Gestão Integrada da Auditoria Médica e Sistemas de Informaçâo: Um Estudo de Caso em uma Cooperativa de Trabalho Médico

Ludmer¹,

Ludmer²

2013

RGSS

View full text Add to dashboard Cite

A situação atual do mercado da saúde suplementar no Brasil e apontamentos para o futuro

Abstract: A situação atual do mercado da saúde suplementar no Brasil e apontamentos para o futuroThe current situation of the private health plans and insurance market in Brazil and trends for the future

Cited by 36 publications

References 5 publications

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Estrutura e qualidade assistencial dos prestadores de serviços hospitalares à saúde suplementar no Brasil

Gestão Integrada da Auditoria Médica e Sistemas de Informaçâo: Um Estudo de Caso em uma Cooperativa de Trabalho Médico

Contact Info

Product

Resources

About